A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder

Summary

The purpose of this study was to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in participants with Obsessive Compulsive Disorder (OCD).

Timeline

Start

2021-01-29

Primary completion

2025-04-29

Completion

2025-04-29

Outcome

Missed primary endpoint

registry LEAST_SQUARES_MEAN Troriluzole: -3.62 (Standard Error 0.446) score on a scale NCT04693351 ↗

registry LEAST_SQUARES_MEAN Placebo: -4.59 (Standard Error 0.454) score on a scale NCT04693351 ↗

registry analysis (superiority test); Troriluzole vs Placebo; p = 0.041; Least squares mean difference 0.97 (95% CI 0.02 to 1.92) NCT04693351 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Troriluzole	Peptide	280 mg	Oral

Indications